Lincoln Pharmaceuticals

Lincoln Pharma Q1 results: Profit up 17% to ₹28 cr, share jumps 8.5%

Lincoln Pharmaceuticals on Thursday reported a nearly 17 per cent growth in net profit to Rs 27.70 crore for the April-June quarter as compared to Rs 23.69 crore in the same quarter of the last fiscal. Total income rose by 7.3 per cent to Rs 169.34 crore in the first quarter of FY26 compared to Rs 157.69 crore in the year-ago period, the company said in a statement. "EBITDA for Q1 FY26 was reported at Rs 39.08 crore as compared to EBITDA of Rs 33.14 crore in Q1 FY25, growth of 17.92 per cent Y-o-Y, the statement said. The company is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets, Lincoln Pharmaceuticals Managing Director Mahendra Patel said. This goal is part of a broader strategy to achieve a 15-18 per cent annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments, Patel added. During the first quarter, the company started its bu

Lincoln Pharma posts Rs 11.62 cr profit for Jan-Mar; revenue at Rs 161 cr

Lincoln Pharmaceuticals on Thursday reported a net profit of Rs 11.62 crore for the March quarter of 2024-25 and said it is building a portfolio in lifestyle and chronic segments, particularly in women's healthcare and dermatology. The Ahmedabad-based company in a statement said that it focuses on expanding its global footprint by registering new products for export and also building a portfolio in lifestyle and chronic segments. The pharma company had reported a net profit of Rs 18.8 crore in the year-ago period. Revenue from operations rose to Rs 161.30 crore in the last quarter of FY25 from Rs 149.51 crore in the year-ago period. "The company remain committed to net debt-free and continues to leverage strategic product launches in both domestic and international markets to strengthen our market presence," Lincoln Pharmaceuticals Managing Director Mahendra Patel said. For the full fiscal, the company reported a net profit of Rs 82.44 crore against Rs 93.36 crore in FY24. Total .

Lincoln Pharma Q1FY25 results: Net profit jumps 24% to Rs 23.67cr

Drug maker Lincoln Pharmaceuticals on Thursday said its consolidated net profit jumped by 24.51 per cent to Rs 23.67 crore in the April-June quarter of 2024-25 compared to Rs 19.01 crore in the year-ago quarter. Total income of the Ahmedabad-bnased company rose by 10 per cent to Rs 157.69 crore in the quarter under review from Rs 143.31 crore in the first quarter of 2023-24. Its operating profit (EBITDA) rose by 16.65 per cent to Rs 33.14 crore in the quarter from Rs 28.41 crore in Q1FY24. Both domestic and export operations have shown robust growth and the company is confident to enhance profitability and margins going forward, the company said in a statement. With focused growth strategies and business expansion plans for value added products and expanding to newer markets, the company is targeting revenue of Rs 750 crore in FY26, it said in the earnings statement. Lincoln Pharmaceuticals shares closed 0.95 per cent down at Rs 652.75 on BSE.

Lincoln Pharma acquires plant for making pneumonia, bronchitis antibiotics

The acquisition along with capacity expansion and modernisation entails an investment of Rs 30 crore which Lincoln Pharma will fund through internal accruals

Lincoln Pharma Q3 net up 23% to Rs 13 cr on strong domestic, global biz

Firm to expand product basket, prepares for entry into European market

Lincoln Pharma gets entry into Europe, will sell derma, gastro drugs

Receives Germany's GMP certification for its Khatraj plant, can sell to all 27 EU markets

Lincoln Pharma plans to foray into regulated markets, upgrades facility

The company has upgraded its manufacturing facility at Khatraj near Ahmedabad with Rs 30-crore investment

Lincoln Pharma gets patent for anti-malarial drug

The drug is painless and gives faster relief to the patients, Lincoln Pharma said

Lincoln Pharmaceuticals gains on launch of oral spray

The Ondansetron Oral Spray has been launched in the dosage form of 0.2ml equivalent to 2mg and 0.4 ml equivalent to 4mg,